The weight loss effect of Novo Nordisk's new drug is not as expected, big dump before the US stock market opens

On December 20th, Jinshi data reported that Novo Nordisk announced on Friday that its experimental next-generation weight-loss drug CagriSema helped overweight patients lose 22.7% of their weight in late-stage trials, lower than the expected 25%, which caused a significant fall in the company's stock price. This lower-than-expected data is a blow to Novo Nordisk, which had hoped that CagriSema would be a more powerful product than its previous generation weight-loss drug Wegovy, to replace it. Investors and analysts have been eagerly awaiting these data to test whether Novo Nordisk has a strong follow-up product to replace Wegovy in the fiercely competitive anti-obesity market. After the results were announced on Friday, Novo Nordisk's stock price fell big dump by 22% in pre-market trading on the US stock market.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)